Science Explorer Back to mapMap

Most cited papers from Minerva Biotechnologies (United States)

What are the most cited papers from Minerva Biotechnologies (United States)?

The most cited paper from Minerva Biotechnologies (United States) is "MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells" (Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta et al., 2009), with 96 citations. Next come "MUC1* Mediates the Growth of Human Pluripotent Stem Cells" (78) and "A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells" (75).

Showing 17 of 17 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta et al. · Breast Cancer Research and Treatment 4 May 2009 96
2 MUC1* Mediates the Growth of Human Pluripotent Stem Cells Sherry T. Hikita, Kenneth S. Kosik, Dennis Clegg et al. · PLoS ONE Open access 2 Oct 2008 78
3 A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells Sanjeev K. Mahanta, Shawn P. Fessler, Jae-Hong Park et al. · PLoS ONE Open access 29 Apr 2008 75
4 Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Thomas N. Seyfried, Jeremy Marsh, Laura M. Shelton et al. · Epilepsy Research Open access Sep 2011 69
5 Differential Proteome Analysis of Extracellular Vesicles from Breast Cancer Cell Lines by Chaperone Affinity Enrichment Steve Griffiths, Michelle A. Cormier, Aled Clayton et al. · Proteomes Open access 8 Oct 2017 52
6 Laminin and Matrix metalloproteinase 11 regulate Fibronectin levels in the zebrafish myotendinous junction Molly H. Jenkins, Sarah S. Alrowaished, Michelle F. Goody et al. · Skeletal Muscle Open access 14 Apr 2016 41
7 A Primitive Growth Factor, NME7AB, Is Sufficient to Induce Stable Naïve State Human Pluripotency; Reprogramming in This Novel Growth Factor Confers Superior Differentiation M.G. Carter, Benoit J. Smagghe, Andrew K. Stewart et al. · Stem Cells Open access 7 Jan 2016 28
8 MUC1* Ligand, NM23-H1, Is a Novel Growth Factor That Maintains Human Stem Cells in a More Naïve State Benoit J. Smagghe, Andrew K. Stewart, Mark G. Carter et al. · PLoS ONE Open access 7 Mar 2013 26
9 A Gold Nanoparticle Platform for Protein–Protein Interactions and Drug Discovery Andrew B. Thompson, Amy K. Calhoun, Benoit J. Smagghe et al. · ACS Applied Materials & Interfaces 23 Jun 2011 24
10 Optimization and validation of an enzyme immunoassay for the insect growth regulator fenoxycarb András Székács, Hong T.M Le, Ferenc Szurdoki et al. · Analytica Chimica Acta 9 Jun 2003 22
11 The VM Mouse Model of Glioblastoma Multiforme Thomas N. Seyfried, Laura M. Shelton, Leanne C. Huysentruyt · Neuromethods Book chapter 2012 4
12 Effective CAR T-cell targeting of an MUC1 cleavage product Benoit J. Smagghe, Mark G. Carter, Kevin Yi et al. · Journal for ImmunoTherapy of Cancer Open access May 2025 3
13 Novel CAR T that targets MUC1* not full-length MUC1 for treatment of solid tumor cancers Cynthia Carol Bamdad, Andrew K. Stewart, Benoit J. Smagghe et al. · Cytotherapy 27 Apr 2018 3
14 First-in-human CAR T for solid tumors targets the MUC1 transmembrane cleavage product Cynthia Carol Bamdad, Andrew K. Stewart, Benoit J. Smagghe et al. · Cytotherapy May 2019 2
15 The Wnt pathway induces a naïve-like subpopulation in primed stem cells, while NME7AB leads to a homogeneous naïve-like population Kevin Yi, Jac-Leen S. Nash, Mark G. Carter et al. · PLoS ONE Open access 25 Jun 2025 0
16 89 First-in-human CAR T targets cleaved MUC1, the growth factor receptor form Benoit J. Smagghe, Andrew K. Stewart, Pengyu Huang et al. · Regular and Young Investigator Award Abstracts Conference paperOpen access Nov 2020 0
17 1st-in-human CAR T targets MUC1 transmembrane cleavage product Cynthia Carol Bamdad, Andrew K. Stewart, Pengyu Huang et al. · Cytotherapy May 2020 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.